Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients.

Creative Commons License

Alıyeva N. , Demır E., Akgul S. , Temurhan S. , Ucar A., Dırım A. B. , ...More

Transplantation proceedings, vol.51, no.4, pp.1118-1120, 2019 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1016/j.transproceed.2019.01.106
  • Journal Name: Transplantation proceedings
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.1118-1120


Introduction. Cardiovascular disease is the leading cause of mortality in kidney transplant recipients. Rituximab is widely used in kidney transplantation for a variety of situations, and rituximab may inhibit some cytokines and antibodies that may play an active role in the atherosclerotic process. The aim of the study was to evaluate the efficacy of rituximab on atherosclerosis biomarkers in kidney transplant recipients.